Study could explain why Parkinson’s drug improves, then diminishes quality of life
Omicron variant is more transmissible but vaccines are still effective
20 January 2022First impressions count and have an impact on the decisions we make later on
20 January 2022Study could explain why Parkinson’s drug improves, then diminishes quality of life
A team of University of California, Irvine researchers has discovered a possible reason why L-dopa, the front-line drug for treating Parkinson’s disease, loses efficacy and causes dyskinesia—involuntary, erratic muscle movements of the patient’s face, arms, legs and torso—as treatment progresses.
